<DOC>
	<DOC>NCT00681369</DOC>
	<brief_summary>the purpose of this study is to describe the way Faslodex is used in France, in patients suffering from initial breast cancer, that is to evaluate Faslodex treatment duration and to determine patients profile</brief_summary>
	<brief_title>Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>fulvestrant</keyword>
	<keyword>longitudinal study</keyword>
	<keyword>France</keyword>
</DOC>